Chemours Company (The) (NYSE:CC) was upgraded by analysts at UBS AG from a “sell” rating to a “neutral” rating in a research report issued on Monday. The firm presently has a $50.00 price target on the specialty chemicals company’s stock, up from their prior price target of $36.00. UBS AG’s target price points to a potential upside of 5.93% from the company’s current price.

A number of other research firms also recently issued reports on CC. J P Morgan Chase & Co upgraded shares of Chemours Company (The) from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $39.00 to $50.00 in a research note on Friday, May 12th. Citigroup Inc. upgraded shares of Chemours Company (The) from a “neutral” rating to a “buy” rating and increased their price objective for the company from $43.00 to $45.00 in a research note on Wednesday, July 5th. Jefferies Group LLC reiterated a “buy” rating and set a $48.00 price objective on shares of Chemours Company (The) in a research note on Friday, June 16th. BidaskClub upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $46.25.

Shares of Chemours Company (CC) opened at 47.20 on Monday. The company has a market capitalization of $8.73 billion, a PE ratio of 30.87 and a beta of 3.63. Chemours Company has a 12 month low of $9.12 and a 12 month high of $50.04. The stock has a 50 day moving average price of $42.16 and a 200-day moving average price of $37.26.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm earned $0.27 earnings per share. The company’s quarterly revenue was up 14.8% on a year-over-year basis. Analysts forecast that Chemours Company will post $3.51 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/chemours-company-the-nysecc-stock-rating-upgraded-by-ubs-ag.html.

In other Chemours Company (The) news, VP Erich Parker sold 4,908 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total value of $223,461.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul Kirsch sold 19,036 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Chemours Company (The) by 48,297.2% in the first quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after buying an additional 19,121,339 shares during the period. Vanguard Group Inc. increased its stake in shares of Chemours Company (The) by 1.2% in the first quarter. Vanguard Group Inc. now owns 18,773,273 shares of the specialty chemicals company’s stock valued at $722,771,000 after buying an additional 215,900 shares during the period. FMR LLC increased its stake in shares of Chemours Company (The) by 36.6% in the first quarter. FMR LLC now owns 14,925,373 shares of the specialty chemicals company’s stock valued at $574,627,000 after buying an additional 3,998,914 shares during the period. State Street Corp increased its stake in shares of Chemours Company (The) by 35.1% in the first quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock valued at $222,987,000 after buying an additional 1,504,657 shares during the period. Finally, Prudential Financial Inc. increased its stake in shares of Chemours Company (The) by 64.1% in the first quarter. Prudential Financial Inc. now owns 4,473,227 shares of the specialty chemicals company’s stock valued at $172,219,000 after buying an additional 1,747,880 shares during the period. Institutional investors own 75.21% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.